Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types.

Hu, Ankang; Wang, Yonghui; Tian, Jiahao; Chen, Zihan; Chen, Renjin; Han, Xufeng; Chen, Yang; Liu, Tingjun; Chen, Quangang

Hu, Ankang; Wang, Yonghui; Tian, Jiahao; Chen, Zihan; Chen, Renjin; Han, Xufeng; Chen, Yang; Liu, Tingjun; Chen, Quangang.

Afiliação

Hu A; Laboratory Animal Center, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Wang Y; School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Tian J; Clinical Medicine Science, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chen Z; Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chen R; School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Han X; School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chen Y; School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Liu T; Laboratory Animal Center, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chen Q; School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu, China.

Front Oncol ; 12: 947054, 2022.

Article em En | MEDLINE | ID: mdl-36505822

Palavras-chave

DDX21; biomarker; immune infiltration; pan-cancer; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google